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AGE intake in a hemodialysis (HD) population, suggesting that correcting malnutrition
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Design and methods:  We investigated this hypothesis in a single center, non-
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and nutritional status were assessed at baseline and 6 months. Results were
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advanced glycation end-product (AGE) intake is associated with a reduction in circulating
AGE levels, suggesting that dietary AGE intake restriction may be also associated with a
decrease in skin autofluorescence (SAF), a marker of AGE accumulation and risk factor for
mortality in the dialysis population. However, we have previously observed an association
between increased SAF and several markers of malnutrition in a hemodialysis population,
whereas higher dietary AGE intake was not associated with increased SAF, raising the
possibility that correction of malnutrition may be a more important strategy to decrease SAF
levels than restriction of dietary AGE intake. In this proof of principle study, we sought to
investigate whether improvement of nutritional status by providing dietetic support would
result in a decrease in SAF in malnourished persons receiving dialysis.
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Impact of dietetic intervention on skin autofluorescence and nutritional status in 
persons receiving dialysis: a proof of principle study. 
 
Objective: Advanced glycation end-products (AGEs) are uremic toxins that result from 
oxidative stress and food consumption. We have previously reported that markers of 
malnutrition are more important determinants of increased skin autofluorescence (SAF), a 
measure of AGE accumulation and risk factor for mortality, than high dietary AGE intake in 
a hemodialysis (HD) population, suggesting that correcting malnutrition may decrease SAF. 
Design and methods: We investigated this hypothesis in a single center, non-randomized 
proof of principle study. We enrolled 27 HD and one peritoneal dialysis (PD) patient with 
malnutrition who received individualized nutritional advice and support over 6 months. SAF 
was measured at baseline, 3 and 6 months. Dietary intake and nutritional status were assessed 
at baseline and 6 months. Results were compared with a control group of malnourished 
dialysis patients (n=41 HD and 8 PD) from a previous observational study.  
Results: The intervention group showed a significant increase in dietary intake, including 
AGEs, Subjective Global Assessment (SGA) score and serum albumin, while SAF levels 
remained stable over 6 months (3.8±0.7 arbitrary units [AU] vs. 3.7±0.7 AU; p=0.3). 
Conversely, in the control group SAF increased significantly during the observation period 
(3.5±0.9 AU vs. 3.8±1.2AU; p=0.03) during which there was no improvement in nutritional 
intake and other markers of nutrition, though dietary AGE intake and SGA score did increase. 
Conclusion: Dietetic support was associated with stable SAF levels despite an increase in 
dietary AGE intake, suggesting that interventions to improve nutrition may be important in 
preventing the rise in SAF observed in malnourished dialysis populations. Further long-term 
studies are needed to test this hypothesis and evaluate the impact on survival. 
Manuscript (without author identifiers) Click here to view linked References
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Advanced glycation end-products (AGEs) are uremic toxins that accumulate in persons on 
dialysis due to reduced renal clearance and increased production1, 2. AGEs cause cross-
linking of tissue proteins and promote inflammation by binding to a specific receptor for 
AGEs (RAGE)3. It seems that collagen in the skin and elastin in vascular basement 
membranes are especially susceptible to AGE accumulation4 and AGE accumulation may 
therefore increase arterial stiffness, a key factor in the pathogenesis of cardiovascular disease 
associated with chronic kidney disease. 
 
Key endogenous pathways leading to the formation of AGEs include hyperglycemia due to 
diabetes, increased oxidative and carbonyl stress, and systemic inflammation. AGEs are also 
formed exogenously, either by cigarette smoking or through food consumption5. High fat and 
high protein diets, dry-heated processed foods and cooking techniques using dry heat and 
high temperatures (e.g. grilling, roasting, broiling, baking and frying) significantly increase 
AGE formation5, 6. On the other hand, malnutrition may also be associated with AGE 
formation by provoking systemic inflammation and oxidative stress7. Due to the fluorescent 
nature of some AGEs, tissue AGE accumulation can be assessed using a non-invasive, 
operator independent and easy to perform technique called skin autofluorescence (SAF), 
which has been shown to be an independent predictor of mortality in the dialysis population3, 
8-10.  
 
Several randomized controlled trials conducted in healthy overweight and/or obese 
volunteers11-13, persons with diabetes and the metabolic syndrome14-16, and in those with 
chronic kidney disease (CKD)17 and performing peritoneal dialysis (PD)18 have reported that 
restriction of dietary AGE intake is associated with a reduction in circulating AGE levels, 
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suggesting that a low AGE diet may be also associated with a decrease in SAF. On the other 
hand, we have previously reported in a cross-sectional analysis conducted in persons on 
hemodialysis (HD) that the presence of malnutrition was associated with higher SAF levels. 
In addition, lower serum albumin, lower handgrip strength (HGS) and lower dietary protein 
intake (all markers of malnutrition) were independent determinants of increased SAF, 
whereas high dietary AGE intake was not associated with higher SAF7. These findings 
suggest that in persons receiving dialysis, correction of malnutrition may be a more important 
strategy to decrease SAF levels than dietary AGE restriction. We therefore aimed to 
investigate whether improvement of nutritional status by providing intensive individualized 





This observational non-randomized proof of principle study initially included 30 HD and 2 
PD patients with malnutrition (i.e. Subjective Global Assessment [SGA] score of <5) who 
were >18 years old and were able to give written informed consent. Participants on HD were 
dialyzing 3-4 times per week for 3-4 hours (12 hours per week) with high-flux polysulphone, 
polyarylethersulfone and/or polyvinylpyrrolidone dialyzers, while PD participants were 
dialyzed using combinations of lactate/bicarbonate-buffered 1.36% glucose (Physioneal; 
Baxter®), 7.5% icodextrin (Extraneal; Baxter®) and/or 1.1% aminoacid-containing solutions 
(Nutrineal; Baxter®). The following exclusion criteria were used: pregnancy or intending 
pregnancy, breastfeeding and having dark skin color. Written informed consent was obtained 
from all participants in accordance with Good Clinical Practice guidelines. This study was 




We considered it unethical to randomize persons with malnutrition to no intervention and 
therefore compared the results of the intervention with a historical control group of 
malnourished persons on dialysis (n=41 HD and 8 PD) taken from a previous observational 
study7, who were assessed at the same time points and using the same methodology.  
 
Data collection 
Hospital electronic medical records were used to collect relevant baseline participant 
characteristics, which included the following: chronological age, sex, ethnicity, dialysis 
vintage (i.e. time since first dialysis treatment), dialysis adequacy, presence of diabetes 
(defined by clinical diagnosis), and history of cardiovascular disease. Information regarding 
educational level, occupation status and history of smoking was obtained by direct interview 
with the patients. Routine clinical blood tests were also recorded at baseline and 6 months. 
 
Intervention  
Participants received individualized nutritional advice and support formulated and delivered 
by experienced dietitians (DVH and FCW) consisting of food fortification recommendations 
and oral nutritional supplementation aiming to achieve estimated nutritional requirements 
(i.e. energy [30-35 kcal/kg/day] and protein intake [1.1-1.2 g/kg/day])19. Participants were 
then followed up for 6 months. Food fortification involved enhancing the energy and protein 
content of meals and snacks without increasing the portion sizes of foods. Advice was 
individualized according to patient needs and food preferences. Oral nutritional supplements 
included Fortisip Compact (2.4 kcal/ml), Fortisip (1.5 kcal/ml) and Fortijuice (1.5 kcal/ml) 
(Nutricia Advanced Medical Nutrition®, Wiltshire, United Kingdom), as well as Renapro® 
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shot (Stanningly Pharma, BioCity, Pennyfoot Street, Nottingham, United Kingdom) and 
Fresubin® 5kcal Shot (Fresenius Kabi Ireland, Balbriggan, Dublin, Ireland).  
 
Participants received precise oral and written instructions on how and when to take the 
supplements and how to follow the food fortification advice provided. Participants were 
closely monitored by the dietitian at least once a week to encourage adherence to nutritional 
advice, and 24-hour dietary recalls were also conducted to ensure compliance with the advice 
provided. Each participant was also reviewed quarterly with the clinical lead renal dietitian 
(FCW) in order to modify the dietetic advice, if required. 
 
Outcome measures 
- Primary outcome: change in SAF levels after 6 months of intensive individualized 
dietetic advice and support. 
- Secondary outcomes: change in nutritional status as assessed by the SGA, nutritional 
intake, dietary AGE intake, anthropometric measurements, HGS and biochemical 
variables after 6 months of intensive individualized dietetic advice and support. 
 
Skin autofluorescence measurement 
Tissue AGE accumulation as assessed by SAF was measured with a validated 
Autofluorescence Reader Standard Unit (SU) version 2.4.3 (AGE Reader SU, DiagnOptics 
Technologies BV, Aarhusweg 4-9, Groningen, The Netherlands) at baseline, 3 and 6 months. 
The technique for measuring SAF has been previously described in more detail by Meerwaldt 
et al.8. In brief, the AGE Reader SU directs an ultraviolet excitation light (wavelength 300-
420 nm) through an illumination window of approximately 1 cm2 on a skin area of the volar 
surface of the forearm at ~10 cm below the elbow. Care is taken to ensure that the area is free 
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of visible vessels, scars, tattoos or any other skin irregularities. The AGE Reader SU then 
measures the amount of light that is reflected back from the skin (i.e. emission light, 
wavelength 300-600 nm) using a spectrometer (AVS-USB2000, Avantes Inc., Eerbeek, The 
Netherlands) and a 200-µm glass fiber. SAF is calculated by dividing the average emitted 
light intensity in the range between 420-600 nm by the average excitation light intensity in 
the range between 300-420 nm, and expressed as arbitrary units (AU).  
 
Three SAF readings were conducted on the non-fistula arm and within the first hour of HD 
treatment in the case of HD participants, while the dominant arm was used in the case of PD 
participants, if this did not have a fistula. The mean value of the three SAF readings was used 
for statistical analyses. Valid SAF readings cannot be obtained when the skin reflectivity is 
lower than 6%20; therefore, persons with dark skin color (i.e. Fitzpatrick skin color type V-
VI), who have an ultraviolet reflectance of less than 6%, were excluded from this study. It 
has been previously reported that SAF readings have good reproducibility and repeatability 
(i.e. coefficient of variation of 7-8%)21. 
 
Nutritional assessments 
Detailed nutritional assessments were undertaken at baseline and 6 months, and included the 
following: 
 
- Dietary intake: Information regarding energy, protein and fat intake was obtained 
from three 24-hour dietary recalls including one dialysis day and one week-end day. 
Participants were asked to recall the type, portion size, source, brand names and 
cooking methods of all foods and drinks they had the day before. Dietary recalls were 
analyzed with the software Dietplan 7 (Forestfield Software Limited, West Sussex, 
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United Kingdom) to calculate the average energy, protein and fat intake. The average 
daily intake of calories and protein was then calculated in kilocalories and grams, 
respectively, and expressed per kilogram of ideal body weight. Quantification of 
AGEs in food was determined with a food frequency questionnaire previously 
validated in a diabetic population22. Dietary AGE intake was reported in kilounits/day 
(kU/day). 
 
- Anthropometry and HGS: Anthropometric measurements were conducted in line with 
international standard methods of assessment23. Post-dialysis weight and height were 
measured to calculate body mass index (BMI; reported in kg/m2), while measurement 
of mid-arm circumference (MAC) and triceps skinfold thickness (TSF), reported in 
cm, was conducted to calculate mid-arm muscle circumference (MAMC) using the 
following equation: MAMC (cm2) = MAC – (3.14 * TSF). HGS measurement was 
conducted within the first hour of HD treatment or during PD clinic visits using the 
Takei 5401 handgrip digital dynamometer (Takei Scientific Instruments Co., Ltd., 
Tokyo, Japan). HGS was measured in the non-fistula arm or the dominant arm if the 
participant did not have a fistula. HGS measurement was ideally conducted in a 
standing position with feet a hip width apart; however, if this was not possible, 
participants were sitting upright on a bed/chair and holding the dynamometer straight 
down and close to their bodies. The dynamometer was adjusted to fit the hand size of 
each participant. Participants were instructed to apply maximum handgrip pressure 
and then relaxed. 
 
- Subjective Global Assessment: The 7-point scale SGA, which is a comprehensive and 
validated nutritional scoring tool24, was performed to evaluate nutritional status. 
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Based on the ratings of six individual core components (i.e. history of weight loss, 
dietary intake, gastrointestinal symptoms, functional status, metabolic stress and 
subjective physical examination of loss of subcutaneous fat and muscle mass), 
nutritional status can be classified into normal nutritional status (scores of 6 or 7), 
mild-moderate malnutrition (scores of 3-5) or severe malnutrition (scores of 1 or 2). 
Because of the nature of the intervention (i.e. dietetic), blinding of participants and 
investigators was not possible. Nevertheless, in order to reduce the risk of bias, 
nutritional status evaluation by SGA was conducted by an experienced dietitian 
(FCW) who did not participate in other methods of nutritional assessment and did not 
conduct SAF measurements. 
 
 Statistical analyses 
All statistical analyses were performed using SPSS version 24.0 (IBM Corporation, Chicago, 
Illinois). Data are expressed as mean ± standard deviation (SD), median (interquartile range 
[IQR]) or percentages, as appropriate. For intragroup comparisons, Wilcoxon test was used in 
the case of continuous variables. Intergroup comparisons were performed using Mann-
Whitney U test for continuous variables and Fisher’s exact test for categorical variables. For 
all statistical analyses, a p-value less than 0.05 was considered to have statistical significance. 
Since this was a proof of principle study, we considered it reasonable to include 40 dialysis 




A total of 188 dialysis patients were assessed for eligibility from January to June 2018. Of 
these, 142 did not meet inclusion criteria, 13 declined to participate and one died after 
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agreeing to take part in the study. A total of 32 dialysis patients were therefore enrolled. Four 
patients did not complete the study protocol (3 deaths and 1 consent withdrawal). Twenty 
eight patients completed 6 months of intervention and were therefore included in the final 
analysis. Historical controls were selected from a previous cohort of 151 dialysis patients7. Of 
these, 56 were classified as being malnourished (i.e. SGA score <5) at baseline. Forty nine 
patients completed 6 months of follow-up (i.e. 5 deaths and 2 transplants) and were included 
in the final analysis (Figure 1).  
 
Baseline participant characteristics 
Demographic, clinical, biochemical and nutritional characteristics of the intervention and 
historical control groups are shown in Table 1. Participants in the intervention group had 
significantly longer dialysis vintage, higher energy and fat intake and lower BMI in 
comparison to the historical control group at baseline, though dietary energy intake was 
below estimated nutritional requirements in both groups. There were no other significant 
differences between the groups at baseline.  
 
Follow-up 
Table 1 shows changes in SAF, biochemical variables and nutritional markers from baseline 
to 6 months. In the intervention group, we observed a significant increase in intake of all 
dietary components, including AGEs (13823 [10840 to 20441] kU/day vs 19074 [13372 to 
27340] kU/day; p=<0.0001), as well as in SGA score and serum albumin. SAF levels did not 
change significantly over 6 months in the intervention group (3.8 ± 0.7 AU vs. 3.7 ± 0.7 AU; 
p=0.3) (Figure 2). In contrast, in the historical control group there was no increase in 
nutritional intake, which remained below estimated nutritional requirements, except for 
dietary AGE intake, which did increase (11940 [8787 to 15833] kU/day vs 14697 [9427 to 
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19071] kU/day; p=0.03). SGA score increased in the historical control group but other 
markers of nutrition did not change. SAF increased significantly in the control group (3.5 ± 
0.9 AU vs. 3.8 ± 1.2 AU; p=0.03) (Figure 2). 
 
DISCUSSION 
In this proof of principle study, we found that intensive individualized dietetic advice and 
support in malnourished persons on dialysis was associated with improvement in dietary 
intake and markers of malnutrition as well as stable SAF levels over 6 months, despite an 
increase in dietary intake of AGEs. In contrast, failure to improve dietary intake in a 
historical control group was associated with an increase in SAF over the same time period. 
 
Malnutrition is a highly prevalent complication in the dialysis population that is very difficult 
to reverse due to the interaction between several etiological factors such as uremic toxicity, 
poor appetite associated with dialysis routine and symptom burden of dialysis resulting in 
inadequate dietary intake, presence of co-morbidities, nutrient losses during dialysis, 
metabolic acidosis, systemic inflammation and oxidative stress25, 26. Nevertheless, in our 
study, we observed that an intensive and individualized dietetic intervention was associated 
with achievement of recommended dietary energy and protein intake19, 27 and with an 
improvement in serum albumin, SGA score and fat intake. A number of interventional studies 
conducted in persons receiving dialysis support our findings that with personalized nutritional 
counselling alone28-30 and/or dietetic advice plus specific oral nutritional supplements31-37 it is 
possible to achieve improvements in nutritional markers including serum albumin, serum 
prealbumin and total cholesterol, energy and protein intake, BMI, TSF and MAC. These 
findings highlight the importance of individualized nutritional advice and support as the 
cornerstone of the treatment of malnutrition in the dialysis population19. 
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In the setting of improved dietary intake and nutritional status, we observed that SAF levels 
remained stable over 6 months in the intervention group. Conversely, in the historical control 
group all components of nutritional intake and other markers of malnutrition did not improve, 
and this was associated with a significant increase in SAF levels. The SGA score did improve 
in the historical control group; however, SGA may be influenced by factors that are not 
directly attributable to nutrition such as infections and other comorbid conditions. Our 
observations support the hypothesis that factors that contribute to the development of 
malnutrition, such as systemic inflammation and oxidative stress, are likely to increase tissue 
AGE accumulation, and malnutrition in turn exacerbates these factors, creating a vicious 
cycle25, 38.  
 
A small number of randomized controlled clinical trials in the CKD and PD populations17, 18, 
39, with small sample sizes and short follow-up periods, have shown that dietary AGE 
restriction was significantly associated with a decrease in serum N-carboxymethyl-lysine and 
methylglyoxal levels (i.e. circulating AGEs). On the other hand, following a high AGE diet 
resulted in a significant increase in these same serum AGEs, suggesting that dietary 
interventions that increase AGE intake may therefore increase SAF. However, we have 
previously reported in a cross-sectional analysis that SAF was significantly higher among 
malnourished persons on HD and that markers of malnutrition such as lower serum albumin, 
lower protein intake and lower HGS were more important determinants of increased SAF 
than high dietary AGE intake, which was not positively associated with SAF7. The present 
intervention study extends these observations by showing that SAF levels stabilized over 6 
months in association with improvements in nutritional status in malnourished persons on 
dialysis, even though dietary AGE intake increased significantly, suggesting that correction 
of malnutrition is a more important intervention to prevent an increase in SAF than restriction 
13 
 
of dietary AGE intake in a dialysis population. The latter may risk exacerbating malnutrition 
and should therefore probably be avoided in those who are malnourished. 
 
This study has some important limitations that need to be highlighted. First, this was a single 
center proof of principle study. Second, the number of participants was small and the follow-
up period was relatively short, which resulted in low statistical power to detect changes in 
some of the variables measured. We did not observe a reduction in SAF in the intervention 
group but this may have been due to the relatively small number of participants and short 
duration of follow-up. Nevertheless, we have established the feasibility of intensive 
individualized dietary intervention to improve nutritional status and stabilize SAF, which 
continued to increase in the historical control group. Further multicenter clinical trials with 
larger sample sizes and longer follow-up are therefore needed to test more robustly whether 
correction of malnutrition may result in a decrease in SAF and improved outcomes. The 
intervention and historical control groups were matched for most variables at baseline, 
though the intervention group evidenced longer dialysis vintage, as well as higher dietary 
energy and fat intake but lower BMI. Dietary energy intake was below estimated nutritional 
requirements in both groups and both were selected for evidence of malnutrition, so we do 
not consider these differences to have impacted our findings. Ideally, this intervention should 
be tested in a prospective randomized controlled trial but we had concerns that not providing 
adequate nutritional support to persons with malnutrition would be unethical. Finally, the 
results observed in this study may not be applicable to populations with dark skin color (who 
were excluded from our study) because SAF measurements cannot be performed in persons 




In conclusion, with intensive individualized dietetic advice and support we observed 
improvement in dietary intake and markers of nutritional status that was associated with 
stable SAF levels over 6 months, despite an increase in dietary AGE intake. In contrast, 
failure to improve dietary intake in a historical control group was associated with an increase 
in SAF. This suggests that individualized nutritional advice and support may be effective in 
preventing the rise in SAF observed in malnourished persons on dialysis over time and that 
the benefits of improving nutritional intake are probably outweighed by any adverse effects 
of increased dietary AGE intake. Studies of nutritional interventions with larger sample sizes 
and longer follow-up are needed to test this hypothesis and evaluate the impact on long-term 
outcomes, including survival. 
 
PRACTICAL APPLICATION 
In this study in malnourished dialysis patients, improved nutritional intake and status was 
associated with stable SAF levels, despite an increase in dietary AGE intake. Persons on 
dialysis who show evidence of malnutrition should therefore be offered individualized 
nutritional advice and support. Further long-term studies of nutritional intervention are 
needed to test the effectiveness of dietetic support in preventing the rise in SAF observed in 
malnourished persons on dialysis and to assess the impact on survival. 
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LEGENDS TO FIGURES 
Figure 1. The Consolidated Standards of Reporting Trials (CONSORT) flowchart of 
participant progression through the study 
Figure 2. Changes in skin autofluorescence during the follow-up period 
AU, arbitrary units. 
*Baseline vs. Month 3; p=0.005 
†Baseline vs. Month 6; p=0.03 
 
Table 1. Changes in skin autofluorescence, biochemical data and nutritional markers from baseline to 6 months in intervention and historical 
control groups 
Variable         Intervention group (n=28)   Historical control group (n=49) 
 Baseline Month 6 p Value Baseline Month 6 p Value 
Age (years) 65 (IQR 56 to 74) --- --- 63 (53 to 75) --- --- 
Male [n (%)] 14 (50) --- --- 23 (47) --- --- 
White ethnicity [n (%)] 24 (86) --- --- 43 (88) --- --- 
Educational qualifications [n (%)] 19 (68) --- --- 27 (55) --- --- 
Unemployed [n (%)] 26 (93) --- --- 41 (84) --- --- 
Current smoking [n (%)] 5 (18) --- --- 14 (29) --- --- 
Diabetes [n (%)] 13 (46) --- --- 18 (37) --- --- 
Coronary heart disease [n (%)] 12 (43) --- --- 25 (51) --- --- 
Dialysis vintage (months) 69.0 (35.0 to 147.0)† --- --- 29.0 (9.5 to 66.0) --- --- 
Serum albumin (g/L) 30.0 (26.0 to 33.0) 31.5 (30.0 to 34.0) 0.01 32.0 (27.0 to 34.0) 31.0 (27.0 to 34.5) 0.9 
C reactive protein (mg/L) 8.5 (2.3 to 30.0) 6.0 (2.0 to 21.8) 0.7 8.0 (3.0 to 22.5) 8.5 (3.0 to 18.8) 0.7 
Total cholesterol (mmol/L) 3.7 (3.2 to 4.7) 3.8 (3.1 to 4.6) 0.5 4.0 (3.1 to 4.9) 4.1 (3.4 to 4.9) 1.0 
Serum creatinine (µmol/L) 508 (403.5 to 623) 587(453 to 667) 0.09 571 (443.5 to 717) 559 (467.5 to 729.5) 0.5 
Serum phosphate (mmol/L) 1.44 (1.19 to 1.82) 1.41 (1.10 to 1.90) 0.9 1.61 (1.25 to 1.85) 1.48 (1.29 to 1.97) 0.4 
Serum potassium (mmol/L) 4.9 (4.2 to 5.5) 4.8 (4.3 to 5.2) 0.3 4.5 (3.9 to 5.2) 4.5 (4.1 to 5.1) 0.6 
Skin autofluorescence (AU) 3.8 ± 0.7 3.7 ± 0.7 0.3 3.5 ± 0.9 3.8 ± 1.2 0.03 
Dietary AGE intake (kU/day) 13823 (10840 to 20441) 19074 (13372 to 27340) <0.0001 11940 (8787 to 15833) 14697 (9427 to 19071) 0.03 
Energy intake (kcal/kg/day) 20.9 (16.6 to 27.3)† 30.1 (24.9 to 35.9) <0.0001 17.9 (13.5 to 21.7) 18.9 (15.1 to 26.9) 0.053 
Protein intake (g/kg/day) 0.7 (0.6 to 1.1) 1.1 (0.8 to 1.2) <0.0001 0.8 (0.6 to 1.0) 0.8 (0.6 to 1.0) 0.9 
Fat intake (g/day) 52.2 (41.1 to 69.8)† 83.5 (67.3 to 98.7) <0.0001 44.8 (33.1 to 59.2) 49.2 (34.3 to 67.6) 0.09 
Dry weight (kg) 60.9 (54.9 to 71.8) 61.4 (56.2 to 70.5) 0.8 66.4 (56.7 to 79.5) 66.8 (55.9 to 79.4) 0.4 
Body mass index (kg/m2) 22.1 (19.8 to 25.1)† 23.0 (20.4 to 24.8) 0.8 25.4 (20.5 to 28.1) 25.0 (20.6 to 29.1) 0.4 
MAMC (cm2) 23.1 (22.3 to 24.5) 23.6 (20.9 to 25.8) 0.3 24.0 (20.8 to 26.6) 24.1 (22.0 to 26.8) 0.2 
Triceps skinfold thickness (mm) 12.9 (8.3 to 15.9) 13.0 (9.0 to 17.0) 0.1 14.6 (10.5 to 18.9) 15.6 (10.6 to 20.0) 0.4 
Handgrip strength (kg) 15.2 (10.4 to 22.3) 16.7 (10.6 to 24.7) 0.8 17.3 (12.2 to 25.6) 18.3 (12.4 to 26.3) 0.053 
SGA score 4.0 (3.25 to 5.0) 5.0 (5.0 to 6.0) <0.0001 5.0 (3.0 to 5.0) 5.0 (3.0 to 7.0) <0.0001 
AGE, advanced glycation end-products; AU, arbitrary units; IQR, interquartile range; kU, kilounits; MAMC, mid-arm muscle circumference; SGA, subjective global assessment.  
† p<0.05 Intervention vs. control at baseline. P-values in columns are for comparison of baseline and 6 month data within each group. 
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